Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: Potential clinical implications

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Marchetti, Antonio ^a   Del Grammastro, Maela ^a   Filice, Giampaolo ^a   Felicioni, Lara ^a   Rossi, Giulio ^b   Graziano, Paolo ^c   Sartori, Giuliana ^b   Leone, Alvaro ^c   Malatesta, Sara ^a   Iacono, Michele ^d   Guetti, Luigi ^a   Viola, Patrizia ^a   Mucilli, Felice ^a   Cuccurullo, Franco ^a   Buttitta, Fiamma ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d Applied Science Roche Diagnostics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GENOMIC DNA;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DNA DETERMINATION; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; GENE DELETION; GENES, ERBB-1; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA;

EID: 84864408769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042164     Document Type: Article

References (32)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA, ((2008)) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc 83:: 584--594.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. ((2004)) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:: 2129--2139.
3. Sun S, Schiller JH, Spinola M, Minna JD, ((2007)) New molecularly targeted therapies for lung cancer. J Clin Invest 117:: 2740--2750.
4. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, et al. ((2010)) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:: 1734--1739.
5. Marchetti A, Felicioni L, Malatesta S, Sciarrotta M, Guetti L, et al. ((2011)) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:: 3574--3579.
6. Pao W, Girard N, ((2011)) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:: 175--180.
7. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. ((2007)) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:: 958--967.
8. Sharma SV, Bell DW, Settleman J, Haber DA, ((2007)) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:: 169--181.
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. ((2009)) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:: 947--957.
10. Lee DH, Park K, Kim JH, Lee JS, Shin SW, et al. ((2010)) Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 16:: 1307--1314.
11. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. ((2010)) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:: 2380--2388.
12. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. ((2010)) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:: 121--128.
13. Yamamoto H, Toyooka S, Mitsudomi T, ((2009)) Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 63:: 315--321.
14. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, et al. ((2006)) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12:: 3908--3914.
15. Sakurada A, Shepherd FA, Tsao MS, ((2006)) Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer 7:: S138--S144.
16. Riely GJ, Politi KA, Miller VA, Pao W, ((2006)) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12:: 7232--7241.
17. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, et al. ((2005)) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:: 857--865.
18. Marchetti A, Felicioni L, Buttitta F, ((2006)) Assessing EGFR mutations. N Engl J Med 354:: 526--8.
19. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, et al. ((2006)) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12:: 1647--1653.
20. Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, et al. ((2006)) EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97:: 753--759.
21. Mardis ER, ((2008)) Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 9:: 387--402.
22. Schuster SC, ((2008)) Next-generation sequencing transforms today's biology. Nat Methods 5:: 16--18.
23. Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, et al. ((2010)) A map of human genome variation from population-scale sequencing. Nature 467:: 1061--1073.
24. Metzker ML, ((2010)) Sequencing technologies-the next generation. Nat Rev Genet 11:: 31--46.
25. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, et al. ((2008)) Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 105:: 13081--13086.
26. De Grassi A, Segala C, Iannelli F, Volorio S, Bertario L, et al. ((2010)) Ultradeep sequencing of a human ultraconserved region reveals somatic and constitutional genomic instability. PLoS Biol 8:: e1000275.
27. Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, et al. ((2007)) Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 28:: 760--770.
28. Penzel R, Sers C, Chen Y, Lehmann-Mühlenhoff U, Merkelbach-Bruse S, et al. ((2011)) EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch 458:: 95--98.
29. Yu J, Kane S, Wu J, Benedettini E, Li D, et al. ((2009)) Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15:: 3023--3028.
30. Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, et al. ((2010)) Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 8:: 135.
31. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. ((2004)) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:: 13306--13311.
32. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. ((2011)) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:: 75ra26.